An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory ...
SYDNEY, March 29, 2023 /CNW/ -- Leading global Foreign Exchange, Commodities, Indices, Share, Precious Metals and CFD broker Axi has announced an extension of its flagship partnership with Manchester ...
SYDNEY, Dec. 12, 2025 (GLOBE NEWSWIRE) -- As global financial markets evolve, Axi is making the case that cryptocurrencies — accessed through its platform and expanding lineup of crypto perpetual ...
SYDNEY, Nov. 28, 2024 (GLOBE NEWSWIRE) -- AxiTrader is excited to announce a new feature for Axi Select traders that provides a fresh start on their trading journey. Effective immediately, Axi Select ...
Hosted on MSN
Axi expands in India with new office opening
Australian foreign exchange and contract for difference (CFD) broker, Axi, has announced the opening of its new office in Bangalore, India. In a social media post, the company announced, "Members of ...
Lessons from the early days of chimeric antigen receptor (CAR) T-cell therapy remain fresh as Kite Pharma prepares for the FDA to act on its supplemental biologics license application for use of ...
The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback